Home » Stocks » ANGO

AngioDynamics, Inc. (ANGO)

Stock Price: $26.50 USD 0.07 (0.26%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
Market Cap 1.02B
Revenue (ttm) 291.01M
Net Income (ttm) -31.55M
Shares Out 38.53M
EPS (ttm) -0.82
PE Ratio n/a
Forward PE 156.25
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $26.50
Previous Close $26.43
Change ($) 0.07
Change (%) 0.26%
Day's Open 26.50
Day's Range 26.21 - 26.69
Day's Volume 94,933
52-Week Range 8.05 - 30.25

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

AngioDynamics exceeded analyst expectations on revenue in Q4 2021, but does that make it worth buying?

1 week ago - The Motley Fool

AngioDynamics (ANGO) registers strong revenue growth across all its GBUs in fiscal 2021 Q4.

2 weeks ago - Zacks Investment Research

AngioDynamics Inc (NASDAQ: ANGO) reports break-even in 4Q of 2021 with adjusted EPS of $0.00, a turnaround from EPS of (0.06) posted a year ago. The Company witnessed the pressure from COVID-19 graduall...

2 weeks ago - Benzinga

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, to...

2 weeks ago - Business Wire

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, to...

3 weeks ago - Business Wire

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, to...

1 month ago - Business Wire

AngioDynamics (ANGO) is optimistic about maintaining its robust product portfolio.

1 month ago - Zacks Investment Research

AngioDynamics (ANGO) gets 510(k) clearance from the FDA for the AlphaVac System for the non-surgical removal of thrombi or emboli from the vasculature.

1 month ago - Zacks Investment Research

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, to...

1 month ago - Business Wire

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, to...

2 months ago - Business Wire

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock?

3 months ago - Zacks Investment Research

Investor optimism is high on AngioDynamics (ANGO) stock, courtesy of its solid prospects.

3 months ago - Zacks Investment Research

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology tod...

3 months ago - Business Wire

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, tod...

3 months ago - Business Wire

AngioDynamics (ANGO) witnesses revenue growth across two business segments in fiscal Q3.

3 months ago - Zacks Investment Research

AngioDynamics (ANGO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the...

3 months ago - Zacks Investment Research

AngioDynamics (ANGO) delivered earnings and revenue surprises of 166.67% and 4.04%, respectively, for the quarter ended February 2021. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Shares of AngioDynamics (NASDAQ:ANGO) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share were up 100.00% year over year to $0.02, which beat the estimate of ...

3 months ago - Benzinga

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, to...

3 months ago - Business Wire

AngioDynamics (NASDAQ:ANGO) unveils its next round of earnings this Tuesday, March 30. Here is Benzinga's everything-that-matters guide for the earnings announcement.

4 months ago - Benzinga

AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, to...

4 months ago - Business Wire

AngioDynamics (ANGO) is optimistic about NanoKnife platform growth and the recent launch of Auryon Atherectomy.

4 months ago - Zacks Investment Research

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, to...

4 months ago - Business Wire

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, to...

4 months ago - Business Wire

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, to...

4 months ago - Business Wire

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock?

5 months ago - Zacks Investment Research

In case a stock falls below the lower bound of this band, it may be time to offload it from your portfolio.

Other stocks mentioned: IBN, LPL, MEC
5 months ago - Zacks Investment Research

Investor confidence is high in AngioDynamics (ANGO) stock, courtesy of its solid prospects.

5 months ago - Zacks Investment Research

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, to...

5 months ago - Business Wire

As of late, it has definitely been a great time to be an investor in AngioDynamics (ANGO).

6 months ago - Zacks Investment Research

Does AngioDynamics (ANGO) have what it takes to be a top stock pick for momentum investors? Let's find out.

6 months ago - Zacks Investment Research

AngioDynamics (ANGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

6 months ago - Zacks Investment Research

AngioDynamics (ANGO) witnesses revenue growth across two business segments in fiscal Q2.

6 months ago - Zacks Investment Research

AngioDynamics, Inc. (ANGO) CEO Jim Clemmer on Q2 2021 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

AngioDynamics (ANGO) delivered earnings and revenue surprises of 150.00% and 8.01%, respectively, for the quarter ended November 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Shares of AngioDynamics (NASDAQ:ANGO) were unchanged in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 83.33% year over year to $0.01, which bea...

6 months ago - Benzinga

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, to...

6 months ago - Business Wire

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, to...

6 months ago - Business Wire

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, to...

7 months ago - Business Wire

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, to...

7 months ago - Business Wire

The RAPID study proved that AngioDynamics' (ANGO) AngioVac System was versatile, safe and effective for the removal of vascular thrombi and cardiac masses.

8 months ago - Zacks Investment Research

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, an...

8 months ago - Business Wire

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock?

9 months ago - Zacks Investment Research

AngioDynamics (ANGO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

9 months ago - Zacks Investment Research

Investor confidence is high in AngioDynamics (ANGO) stock, thanks to solid prospects.

9 months ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in AngioDynamics.

9 months ago - Zacks Investment Research

AngioDynamics (ANGO) witnessed revenue growth across two business segments in fiscal Q1.

9 months ago - Zacks Investment Research

AngioDynamics (ANGO) earnings for the company's fiscal first quarter of 2021 have ANGO stock on the rise Tuesday after beating estimates. The post AngioDynamics Earnings: ANGO Stock Soars 19% on Q1 Topp...

10 months ago - InvestorPlace

AngioDynamics, Inc. (ANGO) CEO Jim Clemmer on Q1 2021 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

About ANGO

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloo... [Read more...]

Industry
Medical Instruments & Supplies
IPO Date
May 27, 2004
CEO
James Clemmer
Country
United States
Stock Exchange
NASDAQ
Ticker Symbol
ANGO
Full Company Profile

Financial Performance

In 2021, AngioDynamics's revenue was $291.01 million, an increase of 10.17% compared to the previous year's $264.16 million. Losses were -$31.55 million, -81.08% less than in 2020.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for AngioDynamics stock is "Buy." The 12-month stock price forecast is 28.00, which is an increase of 5.66% from the latest price.

Price Target
$28.00
(5.66% upside)
Analyst Consensus: Buy